PUBLISHER: The Business Research Company | PRODUCT CODE: 1769624
PUBLISHER: The Business Research Company | PRODUCT CODE: 1769624
In-situ hybridization (ISH) is a molecular technique used to detect and visualize specific DNA or RNA sequences within preserved cells or tissue samples. It functions by applying labeled complementary probes that bind to the target genetic sequences, enabling researchers to observe the localization of specific genes or transcripts while maintaining the integrity of the tissue structure. ISH is widely employed in both research and clinical environments to analyze gene expression, identify chromosomal abnormalities, detect viral infections, and assist in cancer diagnosis, offering comprehensive spatial and molecular insights within biological specimens.
The primary products associated with in-situ hybridization include analytical instruments, kits and reagents, software and services, and other components. Analytical instruments are specialized tools used to detect, measure, and analyze biological, chemical, or physical characteristics within a sample. This technique utilizes several technologies such as fluorescence in situ hybridization, chromogenic in situ hybridization, and dual-color in situ hybridization. It is applied in areas such as cancer diagnosis, cytogenetics, developmental biology, infectious diseases, and immunology. End users include hospitals and diagnostic laboratories, academic and research institutions, contract research organizations, and pharmaceutical and biotechnology companies.
The in-situ hybridization market research report is one of a series of new reports from The Business Research Company that provides in-situ hybridization market statistics, including in-situ hybridization industry global market size, regional shares, competitors with a in-situ hybridization market share, detailed in-situ hybridization market segments, market trends and opportunities, and any further data you may need to thrive in the in-situ hybridization industry. This in-situ hybridization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The in-situ hybridization market size has grown strongly in recent years. It will grow from $1.62 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth during the historic period can be attributed to increased research and development activities, the expansion of biopharmaceutical research, growing government support for genomic research, rising demand for precision medicine therapies, and a higher number of clinical trials utilizing in-situ hybridization (ISH).
The in situ hybridization market size is expected to see strong growth in the next few years. It will grow to $2.53 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to the rising prevalence of cancer, increasing incidence of genetic disorders, growing demand for personalized medicine, greater adoption of companion diagnostics, and heightened awareness regarding early disease diagnosis. Key trends expected during this period include advancements in molecular diagnostics, technological improvements in ISH methods, availability of advanced ISH kits and reagents, increasing demand for non-invasive diagnostic techniques, and progress in fluorescence in-situ hybridization (FISH) technologies.
The increasing incidence of cancer is expected to drive the growth of the in-situ hybridization market in the coming years. Cancer is a disease characterized by the uncontrolled growth of abnormal cells, which can invade surrounding tissues or spread to other parts of the body. The rise in cancer cases is primarily attributed to longer life expectancy, as aging increases the likelihood of accumulating genetic mutations and exposure to cancer-causing agents. In-situ hybridization (ISH) plays a critical role in cancer management by detecting specific genetic abnormalities within tumor cells. It supports accurate diagnosis, prognosis, and helps guide decisions for targeted therapies. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental body, reported that new cancer cases are projected to surpass 35 million by 2050, representing a 77% increase from an estimated 20 million cases in 2022. Thus, the growing incidence of cancer is expected to accelerate the expansion of the in-situ hybridization market.
Leading companies in the in-situ hybridization market are concentrating on the development of advanced solutions, such as HER2 testing technologies, to better predict patient response to targeted treatments. HER2 testing solutions are diagnostic tools designed to detect the presence and expression levels of the HER2 protein in cancer cells, supporting personalized treatment strategies. For example, in December 2023, Cytelabs, an India-based provider of cancer diagnostic services, introduced dual in situ hybridization (DISH) testing for breast cancer patients. This DISH technology, approved by the US FDA, marks a significant advancement in the precision of HER2 testing, which is crucial for effective targeted breast cancer therapy. The method significantly reduces waiting times by delivering HER2 status results within 24 to 48 hours, helping to alleviate the emotional burden on patients and their families. By offering reliable and timely results, DISH facilitates early treatment planning and initiation. As HER2 status is a key factor in determining both prognosis and therapeutic approach, accurate and prompt testing is essential for the effective evaluation of all invasive breast cancers.
In January 2025, Leica Biosystems, a Germany-based biotechnology firm, formed a partnership with Molecular Instruments to enable comprehensive RNA-ISH workflows using the BOND RX and BOND RXm research staining platforms. This collaboration integrates HCR Pro RNA-ISH with Leica Biosystems' existing BOND immunohistochemistry and immunofluorescence methods, enabling the concurrent detection of RNA and proteins within the same tissue section. This advancement provides researchers with enhanced spatial resolution while conserving scarce tissue samples. Molecular Instruments is a biotechnology company based in the United States.
Major players in the in-situ hybridization market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Merck KGaA, Agilent Technologies Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen NV, Bio-Techne Corporation, Leica Biosystems Nussloch GmbH, Biocare Medical LLC, BioGenex Srl, Oxford Gene Technology Inc., BioDot Inc., Creative Biolabs, West Medica Produktions- und Handels GmbH, Empire Genomics LLC, Abnova Corporation, BioView Ltd., Advanced Cell Diagnostics Inc., BioCat GmbH, VERMICON AG, Bio SB Inc., Genemed Biotechnologies Inc.
North America was the largest region in the in-situ hybridization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in in-situ hybridization report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the in-situ hybridization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The in-situ hybridization market consists of revenues earned by entities by providing services such as custom probe design, tissue sample preparation, assay development, multiplexing services, and validation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The in-situ hybridization market also includes sales of slide processing equipment, positive and negative control slides, hybridization chambers, and nuclease-free consumables. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
In-Situ Hybridization Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on in-situ hybridization market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for in-situ hybridization ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The in-situ hybridization market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.